Funding for this research was provided by:
National Institute on Drug Abuse (5R01DA037924)
PRTRUST (PRTRUST: 2015-00050)
National Institute of Minority Health and Health Disparities-RCMI (2U54 MD007600)
Comprehensive Cancer Center, UPR
NIGMS-RISE R25 (GM061838)
PR-INBRE Developmental Research Projects Program (P20 GM103475-15)
Friends of 930 in Memphis, TN and The Ocular Oncology Fund
Received: 5 July 2020
Accepted: 25 December 2020
First Online: 11 January 2021
Ethics approval and consent to participate
: For the use of Rb tumors kindly provided by the public resource facility of the CSTN at STJCRH [CitationRef removed], we obtained IRB approval (Protocol #B0580215) by the institutional IRB committee and for the in vivo studies institutional IACUC approval was obtained (IACUC #A190115). Institutional IRB approval also included the use of human cell lines for this study (Protocol #B0580215).
: Not applicable.
: The authors declare that they have no competing interest.